1. Pharmacogenomics in dermatology: tools for understanding gene-drug associations
- Author
-
Russ B. Altman, Teri E. Klein, Roxana Daneshjou, and Rachel Huddart
- Subjects
Drug ,medicine.medical_specialty ,Databases, Factual ,Drug-Related Side Effects and Adverse Reactions ,business.industry ,media_common.quotation_subject ,Genetic data ,Dermatology ,Skin Diseases ,Article ,Clinical Practice ,Drug treatment ,Knowledge base ,Pharmacogenetics ,Pharmacogenomics ,Health care ,medicine ,Humans ,Surgery ,Dermatologic Agents ,Precision Medicine ,business ,media_common - Abstract
Pharmacogenomics aims to associate human genetic variability with differences in drug phenotypes in order to tailor drug treatment to individual patients. The massive amount of genetic data generated from large cohorts of patients with variable drug phenotypes have led to advances in this field. Understanding the application of pharmacogenomics in dermatology could inform clinical practice and provide insight for future research. The Pharmacogenomics Knowledge Base and the Clinical Pharmacogenetics Implementation Consortium are among the resources to help clinicians and researchers navigate the many gene-drug associations that have already been discovered. The implementation of clinical pharmacogenomics within health care systems remains an area of ongoing development. This review provides an introduction to the field of pharmacogenomics and to current pharmacogenomics resources using examples of gene-drug associations relevant to the field of dermatology.
- Published
- 2019
- Full Text
- View/download PDF